F C Schell
Overview
Explore the profile of F C Schell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
80
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Buzdar A, Blumenschein G, Smith T, POWELL K, Hortobagyi G, Yap H, et al.
Cancer
. 1984 Feb;
53(3):384-9.
PMID: 6362814
Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone...
2.
Yap H, Yap B, Blumenschein G, BARNES B, Schell F, Bodey G
Cancer Res
. 1983 Mar;
43(3):1402-4.
PMID: 6825109
Forty-four patients with metastatic breast cancer who had previously received extensive conventional systemic therapy, including combination chemotherapy with doxorubicin, were treated with Bisantrene, a new anthracene derivative. The dose schedule...
3.
Yap H, Bedikian A, Schell F, Blumenschein G, Bodey G
Am J Clin Oncol
. 1983 Feb;
6(1):31-3.
PMID: 6837505
Thirty-three patients with metastatic breast cancer who have failed prior combination chemotherapy including adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate, were treated with AZQ given on a 5-day I.V. schedule repeated every...
4.
Yap H, Blumenschein G, Hortobagyi G, Buzdar A, Schell F, Bodey G
Am J Clin Oncol
. 1982 Oct;
5(5):511-4.
PMID: 7180829
Forty patients with metastatic breast cancer were treated with a combination of continuous 5-day infusion vinblastine and peptichemio. All patients had received prior therapy with 5-fluorouracil, adriamycin, cyclophosphamide and methotrexate....
5.
Schell F, Yap H, Blumenschein G, Valdivieso M, Bodey G
Cancer Treat Rep
. 1982 Aug;
66(8):1641-3.
PMID: 7105054
Mitoxantrone is a promising new agent developed in an attempt to find drugs with a broad spectrum of antitumor activity and devoid of cardiotoxicity. In a phase II clinical trial...
6.
Buzdar A, Legha S, Blumenschein G, Hortobagyi G, Yap H, Schell F, et al.
Cancer
. 1982 May;
49(9):1767-70.
PMID: 7042074
Peptichemio is a polypeptide complex of L-phenylalanine mustard. Because of structural similarities between melphalan (L-PAM) and Peptichemio a prospective randomized study was done to compare the therapeutic efficacy of these...
7.
Schell F, Yap H, Hortobagyi G, Issell B, Esparza L
Cancer Chemother Pharmacol
. 1982 Jan;
7(2-3):223-5.
PMID: 7083463
No abstract available.
8.
Yap H, Blumenschein G, Schell F, Buzdar A, Valdivieso M, Bodey G
Ann Intern Med
. 1981 Dec;
95(6):694-7.
PMID: 7305147
Thirty-one patients who had metastatic breast cancer extensively pretreated with combination chemotherapy, including doxorubicin, were tested with dihydroxyanthracenedione, 3 to 4 mg/m2 body surface area daily for 5 consecutive days...
9.
Buzdar A, Legha S, Hortobagyi G, Yap H, Wiseman C, Distefano A, et al.
Cancer
. 1981 Jun;
47(12):2798-802.
PMID: 7260870
Sixty-two patients with breast cancer treated with Adriamycin-containing adjuvant chemotherapy developed recurrent disease. Four patients refused to take any form of systemic therapy at the time of relapse. Fifty-eight patients...
10.
Hortobagyi G, Blumenschein G, Buzdar A, Yap H, Schell F, BARNES B, et al.
J Surg Oncol
. 1981 Jan;
18(2):163-72.
PMID: 7300363
In an attempt to prolong the durations of remission and survival of patients with advanced breast cancer treated with the FAC-BCG protocol, we modified the CMF maintenance combination by increasing...